Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.

Quantitative Delta T1 (dT1) as a Replacement for Adjudicated Central Reader Analysis of Contrast-Enhancing Tumor Burden: A Subanalysis of the American College of Radiology Imaging Network 6677/Radiation Therapy Oncology Group 0625 Multicenter Brain Tumor Trial.

Schmainda KM, Prah MA, Zhang Z, Snyder BS, Rand SD, Jensen TR, Barboriak DP, Boxerman JL.

AJNR Am J Neuroradiol. 2019 Jul;40(7):1132-1139. doi: 10.3174/ajnr.A6110. Epub 2019 Jun 27.

PMID:
31248863
2.

Moving Toward a Consensus DSC-MRI Protocol: Validation of a Low-Flip Angle Single-Dose Option as a Reference Standard for Brain Tumors.

Schmainda KM, Prah MA, Hu LS, Quarles CC, Semmineh N, Rand SD, Connelly JM, Anderies B, Zhou Y, Liu Y, Logan B, Stokes A, Baird G, Boxerman JL.

AJNR Am J Neuroradiol. 2019 Apr;40(4):626-633. doi: 10.3174/ajnr.A6015. Epub 2019 Mar 28.

PMID:
30923088
3.

Evaluating Multisite rCBV Consistency from DSC-MRI Imaging Protocols and Postprocessing Software Across the NCI Quantitative Imaging Network Sites Using a Digital Reference Object (DRO).

Bell LC, Semmineh N, An H, Eldeniz C, Wahl R, Schmainda KM, Prah MA, Erickson BJ, Korfiatis P, Wu C, Sorace AG, Yankeelov TE, Rutledge N, Chenevert TL, Malyarenko D, Liu Y, Brenner A, Hu LS, Zhou Y, Boxerman JL, Yen YF, Kalpathy-Cramer J, Beers AL, Muzi M, Madhuranthakam AJ, Pinho M, Johnson B, Quarles CC.

Tomography. 2019 Mar;5(1):110-117. doi: 10.18383/j.tom.2018.00041.

4.

ACRIN 6684: Multicenter, phase II assessment of tumor hypoxia in newly diagnosed glioblastoma using magnetic resonance spectroscopy.

Ratai EM, Zhang Z, Fink J, Muzi M, Hanna L, Greco E, Richards T, Kim D, Andronesi OC, Mintz A, Kostakoglu L, Prah M, Ellingson B, Schmainda K, Sorensen G, Barboriak D, Mankoff D, Gerstner ER; ACRIN 6684 trial group.

PLoS One. 2018 Jun 14;13(6):e0198548. doi: 10.1371/journal.pone.0198548. eCollection 2018.

5.

Multisite Concordance of DSC-MRI Analysis for Brain Tumors: Results of a National Cancer Institute Quantitative Imaging Network Collaborative Project.

Schmainda KM, Prah MA, Rand SD, Liu Y, Logan B, Muzi M, Rane SD, Da X, Yen YF, Kalpathy-Cramer J, Chenevert TL, Hoff B, Ross B, Cao Y, Aryal MP, Erickson B, Korfiatis P, Dondlinger T, Bell L, Hu L, Kinahan PE, Quarles CC.

AJNR Am J Neuroradiol. 2018 Jun;39(6):1008-1016. doi: 10.3174/ajnr.A5675. Epub 2018 May 24.

6.

Toward uniform implementation of parametric map Digital Imaging and Communication in Medicine standard in multisite quantitative diffusion imaging studies.

Malyarenko D, Fedorov A, Bell L, Prah M, Hectors S, Arlinghaus L, Muzi M, Solaiyappan M, Jacobs M, Fung M, Shukla-Dave A, McManus K, Boss M, Taouli B, Yankeelov TE, Quarles CC, Schmainda K, Chenevert TL, Newitt DC.

J Med Imaging (Bellingham). 2018 Jan;5(1):011006. doi: 10.1117/1.JMI.5.1.011006. Epub 2017 Oct 30.

7.

Multisite concordance of apparent diffusion coefficient measurements across the NCI Quantitative Imaging Network.

Newitt DC, Malyarenko D, Chenevert TL, Quarles CC, Bell L, Fedorov A, Fennessy F, Jacobs MA, Solaiyappan M, Hectors S, Taouli B, Muzi M, Kinahan PE, Schmainda KM, Prah MA, Taber EN, Kroenke C, Huang W, Arlinghaus LR, Yankeelov TE, Cao Y, Aryal M, Yen YF, Kalpathy-Cramer J, Shukla-Dave A, Fung M, Liang J, Boss M, Hylton N.

J Med Imaging (Bellingham). 2018 Jan;5(1):011003. doi: 10.1117/1.JMI.5.1.011003. Epub 2017 Oct 10.

8.

Spatial discrimination of glioblastoma and treatment effect with histologically-validated perfusion and diffusion magnetic resonance imaging metrics.

Prah MA, Al-Gizawiy MM, Mueller WM, Cochran EJ, Hoffmann RG, Connelly JM, Schmainda KM.

J Neurooncol. 2018 Jan;136(1):13-21. doi: 10.1007/s11060-017-2617-3. Epub 2017 Sep 12.

9.

ACRIN 6684: Assessment of Tumor Hypoxia in Newly Diagnosed Glioblastoma Using 18F-FMISO PET and MRI.

Gerstner ER, Zhang Z, Fink JR, Muzi M, Hanna L, Greco E, Prah M, Schmainda KM, Mintz A, Kostakoglu L, Eikman EA, Ellingson BM, Ratai EM, Sorensen AG, Barboriak DP, Mankoff DA; ACRIN 6684 Trial Group.

Clin Cancer Res. 2016 Oct 15;22(20):5079-5086. Epub 2016 May 16.

10.

Repeatability of Standardized and Normalized Relative CBV in Patients with Newly Diagnosed Glioblastoma.

Prah MA, Stufflebeam SM, Paulson ES, Kalpathy-Cramer J, Gerstner ER, Batchelor TT, Barboriak DP, Rosen BR, Schmainda KM.

AJNR Am J Neuroradiol. 2015 Sep;36(9):1654-61. doi: 10.3174/ajnr.A4374. Epub 2015 Jun 11.

11.

Dynamic susceptibility contrast MRI measures of relative cerebral blood volume as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 multicenter trial.

Schmainda KM, Zhang Z, Prah M, Snyder BS, Gilbert MR, Sorensen AG, Barboriak DP, Boxerman JL.

Neuro Oncol. 2015 Aug;17(8):1148-56. doi: 10.1093/neuonc/nou364. Epub 2015 Feb 2.

12.

Dynamic-susceptibility contrast agent MRI measures of relative cerebral blood volume predict response to bevacizumab in recurrent high-grade glioma.

Schmainda KM, Prah M, Connelly J, Rand SD, Hoffman RG, Mueller W, Malkin MG.

Neuro Oncol. 2014 Jun;16(6):880-8. doi: 10.1093/neuonc/not216. Epub 2014 Jan 15.

13.

The effect of pulse sequence parameters and contrast agent dose on percentage signal recovery in DSC-MRI: implications for clinical applications.

Boxerman JL, Paulson ES, Prah MA, Schmainda KM.

AJNR Am J Neuroradiol. 2013 Jul;34(7):1364-9. doi: 10.3174/ajnr.A3477. Epub 2013 Feb 14.

14.

Effects of perfusion on diffusion changes in human brain tumors.

Cohen AD, LaViolette PS, Prah M, Connelly J, Malkin MG, Rand SD, Mueller WM, Schmainda KM.

J Magn Reson Imaging. 2013 Oct;38(4):868-75. doi: 10.1002/jmri.24042. Epub 2013 Feb 6.

15.

Vascular change measured with independent component analysis of dynamic susceptibility contrast MRI predicts bevacizumab response in high-grade glioma.

LaViolette PS, Cohen AD, Prah MA, Rand SD, Connelly J, Malkin MG, Mueller WM, Schmainda KM.

Neuro Oncol. 2013 Apr;15(4):442-50. doi: 10.1093/neuonc/nos323. Epub 2013 Feb 3.

16.

Presumed hydrogen sulfide-mediated neurotoxicity after streptococcus anginosus group meningitis.

Verma S, Landisch R, Quirk B, Schmainda K, Prah M, Whelan HT, Willoughby RE Jr.

Pediatr Infect Dis J. 2013 Feb;32(2):189-91. doi: 10.1097/INF.0b013e3182748fe9.

Supplemental Content

Support Center